A single infectious bite with vivax malaria can cause multiple malaria episodes through dormant liver parasites. Radical cure is needed to clear these liver parasites, but the drug can cause haemolysis in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. Up until recently, options for point-of-care tests for G6PD deficiency have been limited. We have developed decision analytic models to evaluate the cost-effectiveness of vivax malaria patient management, including G6PD screening strategies and radical cure regimens. See our online tool on the cost-effectiveness of screening before primaquine treatment. The model is currently being expanded to include qualitative G6PD tests and tafenoquine.